
MEDISEARCHER NEWS
United States · Medication safety · 10 November 2026
In brief
- On 9 November 2026, the US Food and Drug Administration (FDA) announced that all GLP-1 receptor agonist medicines must carry updated warnings about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
- The affected medicines include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda and other GLP-1 treatments.
- NAION is a rare condition involving reduced blood flow to the optic nerve that can cause sudden, painless and potentially permanent vision loss.
- An FDA analysis of 126 randomised clinical trials found 6.4 NAION cases per 100,000 person-years among GLP-1 users, compared with 3.8 among comparator patients.
- The FDA’s observational evidence was mixed, and the agency has not established a specific biological mechanism explaining the potential association.
- Patients experiencing sudden vision loss or other significant new visual disturbances should seek immediate medical assessment. Patients without symptoms should not independently stop prescribed treatment.
- The European Medicines Agency and UK regulators had previously addressed NAION warnings for semaglutide; the new FDA action covers the broader GLP-1 class.
The US Food and Drug Administration has ordered new safety warnings for widely prescribed diabetes and weight-loss medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, following a review of evidence linking GLP-1 receptor agonists to a rare but potentially serious eye condition.
In a Drug Safety Communication issued on 9 November 2026, the FDA announced that manufacturers must add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions sections of GLP-1 medicine labels.
NAION can cause sudden, painless loss of vision, usually in one eye. In some cases, the resulting vision impairment is permanent.
The decision is significant because it extends beyond semaglutide, the active ingredient in Ozempic and Wegovy, to the wider class of GLP-1 medicines, including tirzepatide products such as Mounjaro and Zepbound.
However, the FDA also emphasises that NAION is rare. Its findings should not be interpreted as evidence that everyone taking a GLP-1 medicine faces a substantial risk of blindness.
What exactly has the FDA changed?
The FDA is requiring application holders for all GLP-1 receptor agonist medicines to add information about the potential risk of NAION to their official prescribing information.
This is a class-wide safety-label change, rather than a warning limited to one manufacturer or medicine.
The action follows the agency’s review of randomised clinical trials, observational research, post-marketing safety reports and animal studies.
FDA investigators found a small number of NAION events across clinical trials and identified evidence suggesting a possible increased risk among GLP-1 users.
The agency also examined whether other factors, including diabetes, high blood pressure and cardiovascular risk, could complicate interpretation of the findings.
The new warning is intended to ensure that patients and healthcare professionals understand the potential risk, recognise symptoms and respond promptly if vision changes occur.
The announcement does not withdraw approval for Ozempic, Wegovy, Mounjaro or other GLP-1 medicines.
Which GLP-1 medicines are affected?
The FDA’s decision covers all GLP-1 receptor agonist medicines included in the agency’s safety communication.
| Medicine | Active ingredient | Common treatment area |
|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes and certain related risk-reduction indications |
| Wegovy | Semaglutide | Weight management and certain related indications |
| Rybelsus | Semaglutide | Type 2 diabetes |
| Mounjaro | Tirzepatide | Type 2 diabetes |
| Zepbound | Tirzepatide | Weight management and certain related indications |
| Trulicity | Dulaglutide | Type 2 diabetes |
| Victoza | Liraglutide | Type 2 diabetes |
| Saxenda | Liraglutide | Weight management |
| Foundayo | Orforglipron | Weight management |
| Soliqua | Lixisenatide and insulin glargine | Type 2 diabetes |
| Xultophy | Liraglutide and insulin degludec | Type 2 diabetes |
| Generic exenatide | Exenatide | Type 2 diabetes |
Tirzepatide acts on both GIP and GLP-1 receptors and is included in the FDA’s GLP-1 safety review.
Product availability and approved indications differ between countries. The FDA action applies to US medicine labelling and does not automatically change European or UK product information.
What is NAION and can it cause permanent blindness?
Non-arteritic anterior ischemic optic neuropathy (NAION) is an eye condition caused by reduced blood flow to the front portion of the optic nerve.
The optic nerve carries visual information from the eye to the brain. When its blood supply is disrupted, nerve tissue can be damaged, resulting in vision loss.
NAION typically affects one eye and often develops suddenly, sometimes becoming noticeable when a person wakes up.
The condition is generally painless.
Symptoms can include:
- sudden reduction or loss of vision in one eye;
- blind spots or missing sections of the visual field;
- tunnel vision;
- blurred or hazy central vision; and
- changes in colour perception.
Some people experience partial visual impairment, while others can lose substantial vision in the affected eye.
NAION-related damage can be permanent, although the degree of impairment varies.
Sudden vision loss is a medical emergency because several different eye and neurological conditions can cause similar symptoms.
How common is NAION among GLP-1 users?
The FDA analysed data from 126 randomised controlled trials involving 134,253 participants.
Of these, 78,217 received GLP-1 receptor agonists and 56,036 received placebo or another glucose-lowering medicine.
Across the trials, investigators identified 15 probable NAION events:
- 10 among participants receiving GLP-1 medicines;
- five among participants receiving placebo; and
- none among participants receiving other non-GLP-1 glucose-lowering medicines.
Because participants were followed for different lengths of time, the FDA expressed the findings as events per 100,000 person-years.
| Study group | NAION incidence per 100,000 person-years |
|---|---|
| GLP-1 receptor agonist users | 6.4 |
| Comparator group | 3.8 |
| Observed difference | 2.6 additional cases |
In practical terms, the observed difference was approximately 2.6 additional NAION cases per 100,000 person-years of treatment in the pooled clinical-trial data.
That is a small absolute difference, although the consequences for an individual affected by NAION can be serious.
The estimate is based on only 15 probable events and should not be treated as a precise prediction of risk for every patient or individual GLP-1 medicine.
Does this mean Ozempic or Mounjaro causes blindness?
The FDA’s conclusion is more cautious than that.
The agency identified a potential increased risk of NAION associated with GLP-1 receptor agonists.
It did not establish that every reported case of NAION was caused by the medicine, nor did it identify a definitive biological mechanism linking GLP-1 treatment to optic-nerve damage.
This distinction matters because many people taking GLP-1 medicines already have conditions associated with NAION.
Known or suspected risk factors include:
- type 2 diabetes;
- high blood pressure;
- sleep apnoea;
- smoking;
- anaemia; and
- kidney disease.
These overlapping risks make it difficult to determine how much of the observed association is attributable directly to treatment.
Nevertheless, the FDA concluded that the available evidence was sufficient to justify a class-wide safety warning.
What did the FDA’s real-world study find?
In addition to clinical trials, the FDA examined real-world healthcare data involving adults with type 2 diabetes who started GLP-1 medicines or other commonly prescribed diabetes treatments between 2019 and 2024.
The study compared GLP-1 users with patients receiving two other classes of diabetes medicine:
- SGLT-2 inhibitors, which include medicines such as empagliflozin and dapagliflozin; and
- DPP-4 inhibitors, which include medicines such as sitagliptin.
The FDA found that GLP-1 users had a statistically significant higher observed risk of NAION compared with DPP-4 inhibitor users.
The reported hazard ratio was 1.43, corresponding to a 43% higher relative hazard in that comparison.
However, the comparison with SGLT-2 inhibitors did not show a statistically significant increase.
The hazard ratio in that comparison was 1.19, with a 95% confidence interval of 0.91 to 1.54.
The real-world findings therefore provide supporting evidence for a possible association, but they also illustrate why the magnitude of risk remains uncertain.
Relative-risk figures should not be confused with the absolute probability that an individual patient will develop NAION.
What should patients taking Ozempic, Wegovy or Mounjaro do?
The FDA advises patients to be aware of symptoms of NAION and to contact a healthcare professional immediately if sudden visual changes occur.
Warning signs include sudden painless vision loss in one eye, new blind spots, tunnel vision, distorted colours or a sudden reduction in central visual sharpness.
Patients experiencing sudden vision loss should seek urgent medical assessment rather than waiting for a routine appointment.
Healthcare professionals should promptly refer patients with suspected NAION to an ophthalmologist.
The FDA advises clinicians to consider discontinuing the GLP-1 medicine when NAION develops, unless the benefits of continued treatment clearly outweigh the risks.
Patients who have previously experienced NAION should discuss their individual risks and treatment options with their prescribing clinician.
Patients without visual symptoms should not independently discontinue prescribed diabetes or weight-loss treatment solely because of the new warning.
Stopping treatment can have consequences for blood glucose control, weight management and other conditions for which these medicines are prescribed.
What if you have already had NAION in one eye?
Patients who have experienced NAION in one eye have an increased risk of developing the condition in the other eye.
The FDA specifically advises people with a history of NAION to discuss whether they should continue using a GLP-1 medicine.
This requires an individual assessment of the medicine’s benefits, the patient’s existing medical conditions and their ophthalmological history.
A previous NAION diagnosis does not automatically establish that a GLP-1 medicine caused the event.
However, it is important information for the treating clinician when considering continued treatment.
How does the new FDA warning compare with Europe?
European regulators had already examined a possible association between semaglutide and NAION before the FDA’s November 2026 announcement.
In June 2025, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION should be listed as a very rare side effect of semaglutide-containing medicines, including Ozempic, Rybelsus and Wegovy.
The EMA described the risk as potentially affecting up to one in 10,000 people taking semaglutide.
The European review was focused on semaglutide rather than requiring a class-wide warning across all GLP-1 receptor agonists.
The FDA’s November 2026 decision is therefore broader in scope because it covers the entire GLP-1 class, including tirzepatide.
These differences do not necessarily mean that European and US regulators disagree about the underlying evidence. They reflect regulatory decisions made at different times and concerning different product scopes.
Patients in the EU should follow current national and European product information and discuss concerns with their healthcare professionals.
What has the UK said about GLP-1 medicines and vision loss?
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) updated its safety advice concerning semaglutide and NAION in February 2026.
The MHRA advised healthcare professionals and patients to recognise sudden vision changes and seek urgent medical assessment when appropriate.
Like the earlier European review, the UK action concerned semaglutide products.
The new FDA class-wide warning should not be interpreted as an automatic amendment to UK prescribing information for every GLP-1 medicine.
Patients should continue to consult current MHRA safety information and the product information applicable in the United Kingdom.
Does the new warning change the benefits of GLP-1 treatment?
GLP-1 receptor agonists have become important treatments for type 2 diabetes and obesity.
Several medicines in the class also have approved indications involving cardiovascular risk reduction, kidney disease, obstructive sleep apnoea or other serious conditions.
For eligible patients, these treatments can provide substantial clinical benefits.
The new FDA warning adds information about a rare potential adverse effect that should be considered alongside those benefits.
It does not mean that the medicines have been withdrawn or that they are unsuitable for everyone.
Prescribing decisions should account for the individual’s medical history, treatment response, alternative therapies and risk factors.
Patients should be informed about symptoms that require urgent assessment without being encouraged to abandon beneficial treatment unnecessarily.
Why did the FDA investigate NAION and GLP-1 medicines?
Concerns about a possible association gained attention following a study published in JAMA Ophthalmology in July 2024.
The study examined the risk of NAION among patients prescribed semaglutide.
The FDA identified limitations in that research but concluded that the findings warranted further investigation.
Its subsequent assessment included:
- randomised clinical-trial data across multiple GLP-1 medicines;
- post-marketing adverse-event reports;
- observational studies involving real-world healthcare data;
- the FDA’s Sentinel real-world evidence programme; and
- available animal research.
The FDA noted that spontaneous adverse-event reports were difficult to interpret because many GLP-1 users already have NAION risk factors.
Its animal-data review did not identify a clear mechanism explaining the potential association.
Nevertheless, the combined evidence led the agency to require the updated warnings.
What happens next?
Manufacturers of affected GLP-1 medicines must update the Warnings and Precautions sections of their US prescribing information in accordance with the FDA’s requirements.
The new safety information may also influence discussions between patients, prescribers, pharmacists and ophthalmologists.
Further research will be important to determine whether the risk differs between individual GLP-1 medicines, whether particular patient groups are more susceptible and how much of the observed association is directly attributable to treatment.
Regulators outside the United States may continue evaluating the evidence and update their own product information when warranted.
MediSearcher will monitor material changes to FDA, EMA and MHRA safety guidance.
Frequently asked questions
Has the FDA added a blindness warning to Ozempic?
The FDA announced on 9 November 2026 that Ozempic and other GLP-1 medicines must carry updated warnings about a potential increased risk of NAION, a rare condition that can cause sudden and sometimes permanent vision loss.
Does the new warning include Mounjaro and Zepbound?
Yes. The FDA’s action covers tirzepatide-containing products, including Mounjaro and Zepbound, as part of its broader GLP-1 class-wide warning.
How likely is vision loss from GLP-1 medicines?
In the FDA’s pooled clinical-trial analysis, NAION occurred at a rate of 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases per 100,000 person-years among comparator patients. NAION remains rare, and individual risk can vary.
What are the warning signs of NAION?
Symptoms include sudden, painless loss of vision in one eye, blind spots, tunnel vision, changes in colour perception and blurred or hazy central vision. Sudden visual changes require urgent medical assessment.
Should I stop taking Wegovy or Ozempic?
Patients should not independently stop prescribed treatment solely because of the warning. Anyone experiencing sudden vision changes should seek urgent medical attention. A healthcare professional can assess whether treatment should be continued or discontinued.
Is NAION permanent?
NAION can cause lasting optic-nerve damage and permanent vision impairment. The severity varies, but prompt assessment is important because sudden vision loss can have several possible causes.
Has Europe issued the same warning?
European regulators previously identified NAION as a very rare adverse effect of semaglutide medicines. The FDA’s November 2026 action is broader because it covers the entire GLP-1 class, including tirzepatide.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: This article was prepared using the FDA’s 9 November 2026 Drug Safety Communication, including its analysis of 126 randomised clinical trials and real-world evidence, together with European and UK regulatory information concerning semaglutide and NAION. It distinguishes potential association from established causation, absolute from relative risk, and the US class-wide warning from earlier European product-specific decisions.
Last reviewed: 10 November 2026
Sources and verification
MediSearcher reviewed the following primary regulatory and scientific sources:
- US Food and Drug Administration: FDA Requires Safety Labeling Changes for GLP-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition, 9 November 2026
- FDA MedWatch: Patient and healthcare-professional safety recommendations, 9 November 2026
- European Medicines Agency: PRAC concludes NAION is a very rare side effect of semaglutide medicines, June 2025
- UK Medicines and Healthcare products Regulatory Agency: Semaglutide and risk of NAION, February 2026
- JAMA Ophthalmology: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide, 2024
MediSearcher provides general information about medicines, medicine safety and healthcare regulation. This article does not provide personal medical advice. NAION is rare but can cause permanent vision impairment. Anyone experiencing sudden vision loss or significant new visual symptoms should seek urgent medical attention. Patients should not independently discontinue prescribed diabetes or weight-loss treatment without discussing their circumstances with an appropriately qualified healthcare professional.